LeMaitre Vascular (NASDAQ:LMAT) Shares Pass Above 200 Day Moving Average – What’s Next?
by Amy Steele · The Cerbat GemShares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $92.90 and traded as high as $114.60. LeMaitre Vascular shares last traded at $112.80, with a volume of 94,397 shares.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Barrington Research lifted their target price on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Roth Mkm reiterated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Citizens Jmp lifted their target price on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Finally, Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $105.80.
View Our Latest Research Report on LMAT
LeMaitre Vascular Stock Performance
The stock has a market cap of $2.59 billion, a P/E ratio of 45.20, a P/E/G ratio of 3.25 and a beta of 0.67. The company has a fifty day moving average price of $107.21 and a 200 day moving average price of $93.22. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The firm had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.
LeMaitre Vascular Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were issued a dividend of $0.25 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is presently 39.84%.
Insider Activity
In related news, CEO George W. Lemaitre sold 55,930 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares in the company, valued at approximately $159,181,465. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 215,438 shares of company stock worth $23,062,911 over the last quarter. 9.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On LeMaitre Vascular
Several institutional investors have recently bought and sold shares of the stock. James Investment Research Inc. bought a new stake in LeMaitre Vascular during the first quarter worth $243,000. Pictet Asset Management Holding SA grew its holdings in LeMaitre Vascular by 5.5% during the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock worth $356,000 after buying an additional 169 shares in the last quarter. Wesbanco Bank Inc. grew its holdings in LeMaitre Vascular by 13.8% during the first quarter. Wesbanco Bank Inc. now owns 19,800 shares of the medical instruments supplier’s stock worth $2,162,000 after buying an additional 2,400 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in LeMaitre Vascular during the first quarter worth $1,015,000. Finally, Riverbridge Partners LLC purchased a new position in LeMaitre Vascular in the first quarter worth $11,528,000. Institutional investors own 84.64% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.